OR WAIT null SECS
The COVID-19 pandemic has led to many changes in how pharmaceutical companies develop vaccines.
More technologies and treatments are emerging for COVID-19—along with new variants.
Partnerships formed during the COVID-19 pandemic have provided a platform for change in assay development and transfers.
January 03, 2021
Biopharma looks to deliver on COVID-19 vaccines and other promising therapies.
Despite the COVID-19 pandemic disruptions, with continued support and industry resilience, the European bio/pharma outlook for 2021 is positive.
January 02, 2021
Boreas from Telstar are -86 ºC ultra-low-temperature freezers developed to house COVID-19 vaccines.
December 31, 2020
Administration of the COVID-19 vaccination from Oxford University and AstraZeneca is expected to begin in the UK in early 2021.
A report in the New England Journal of Medicine states preliminary results from a Phase III clinical trial shows the vaccine is 94.1% effective.
December 30, 2020
President Trump signed the COVID-19 package, which appropriates $2.3 trillion to finance the federal government through September 2021 and provides support for individuals and entities suffering from the economic crisis wrought by the pandemic.
December 23, 2020
The agency is organizing a second public meeting on January 8, 2021 to discuss the assessment, approval, and roll-out of new COVID-19 vaccines.
December 21, 2020
Moderna’s mRNA vaccine to prevent COVID-19 disease is granted FDA Emergency Use Authorization and CDC recommendation.
A decision by the European Commission on conditional marketing authorization for the European Union’s first COVID-19 vaccine is expected soon.
December 18, 2020
The agency is answering frequently asked questions about the Pfizer–BioNTech COVID-19 vaccine on its website.